Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
08/12/14
2014 Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
08/12/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/11/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/08/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
07/31/1410-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
07/31/148-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>
There are currently no items available.

Fact Sheets

DateTitle
01/20/12
EXPAREL® Fact Sheet PDF
05/03/13
DepoFoam® Backgrounder PDF
05/06/11
Postsurgical Pain Backgrounder PDF

Recent Press Releases

DateTitle 
08/05/14Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 8:35 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
07/31/14Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2014. “With nine quarters now under our belt, we are pleased wi... 
Printer Friendly Version
07/17/14Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2014, will be released before the market opens on Thursday, July 31, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 31, 2014, at 9 a.m. ET. The call can be ac... 
Printer Friendly Version
06/26/14Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
-- Multi-study Analysis Published in Journal of Pain Research Reinforces Value of EXPAREL-Based Multimodal Analgesia Regimen -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 26, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® (bup... 
Printer Friendly Version
05/27/14Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at investor conferences during June. Mr. Stack will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 11 a.m. ET in New York. ... 
Printer Friendly Version
05/07/14Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
Expected PDUFA Date of March 5, 2015 PARSIPPANY, N.J.--(BUSINESS WIRE)--May 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL® (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAR... 
Printer Friendly Version
05/05/14Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 8 a.m. PT in Las Vegas. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Paci... 
Printer Friendly Version
05/01/14Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May 1, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2014. “We are excited by the continued success of EXPA... 
Printer Friendly Version
04/17/14Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company’s first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/15/14Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4). Pacira granted to 17 new ... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com